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Patients with bone metastases from breast cancer often experience substantial skeletal complications – including debilitating bone
pain – which negatively affect quality of life. Zoledronic acid (4mg) has been demonstrated to reduce significantly the risk of skeletal
complications in these patients and is administered via a short, 15-min infusion every 3 weeks, allowing the possibility for home
administration. This study compared the efficacy and safety of zoledronic acid administered in the community setting vs the hospital
setting in breast cancer patients with X1 bone metastasis receiving hormonal therapy. After a lead-in phase of three infusions of 4mg
zoledronic acid in the hospital setting, 101 patients were randomized to receive three open-label infusions in the community or
hospital setting, followed by three infusions in the opposite venue (a total of nine infusions). The Brief Pain Inventory (BPI) and the
European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) were
used to assess potential benefits of zoledronic acid therapy. At study end, analysis of the BPI showed significant reductions in worst
pain (P¼0.008) and average pain in the last 7 days (P¼0.039), and interference with general activity (P¼0.012). In each case, there
were significantly greater improvements in pain scores after treatment in the community setting compared with the hospital
crossover setting for worst pain (P¼0.021), average pain (P¼0.003), and interference with general activity (P¼0.001). Overall
global health status showed a significant median improvement of 8.3% (P¼0.013) at study end. Physical, emotional, and social
functioning also showed significant overall improvement (P¼0.013, 0.005, and 0.043, respectively). Furthermore, physical, role, and
social functioning showed significantly greater improvements after treatment in the community setting compared with the hospital
crossover setting (P¼0.018, 0.001, and 0.026, respectively). There was no difference between hospital and community
administration in renal or other toxicity, with zoledronic acid being well tolerated in both treatment settings. These data confirm the
safety and quality-of-life benefits of zoledronic acid in breast cancer patients with bone metastases, particularly when administered in
the community setting.
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Each year, more than one million women will develop breast
cancer worldwide with nearly half of these diagnoses occurring in
the United States and Europe. Ultimately, more than 400000 of
these women will die of their disease (Parkin et al, 2005). Globally,
breast cancer has the highest incidence of all cancers and is the
leading cause of cancer mortality in women, accounting for
approximately 23% of new cancer cases and approximately 14% of
cancer deaths (Parkin et al, 1999). Metastasis to bone is
common during disease progression and affects an estimated
65–75% of patients with advanced breast cancer (Coleman, 2001).
Resulting bone lesions lead to substantial skeletal complications
that negatively affect quality of life (Coleman, 2001). Median
survival for patients with advanced breast cancer is approximately
18–26 months after the initial diagnosis of bone metastases,
placing patients at long-term risk of developing skeletal complica-
tions (Domchek et al, 2000; Coleman, 2001). Therefore, treatment
and prevention of skeletal complications could improve quality-of-
life outcomes and result in clinical benefits for these patients.
Zoledronic acid is a new-generation nitrogen-containing bi-
sphosphonate with evidence of significant efficacy in the treatment
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sof bone lesions from multiple myeloma or a variety of solid
tumours, including breast, prostate, lung, and renal cell cancer
(Lacerna and Hohneker, 2003). In a long-term, randomised, phase
III clinical trial, zoledronic acid (4mg via 15-min infusion) was
superior to pamidronate (90mg via 2-h infusion), the previous
standard of care, for reducing the risk of skeletal complications in
patients with breast cancer metastatic to bone (Rosen et al, 2003,
2004).
Several studies have demonstrated that bisphosphonates have an
analgesic effect in patients with bone metastases. In a long-term
follow-up of two large, randomised trials in breast cancer patients,
pamidronate (90mg) significantly improved pain scores and
reduced need for palliative radiation therapy compared with
placebo (Po0.001) (Hortobagyi et al, 1998; Theriault et al, 1999;
Lipton et al, 2000). In studies comparing zoledronic acid (4mg)
with pamidronate (90mg) in patients with bone lesions from
multiple myeloma or breast cancer, zoledronic acid significantly
reduced the need for radiation to bone compared with pami-
dronate (19 vs 24% for pamidronate; P¼0.037), and was at least as
effective as pamidronate for the palliation of bone pain. Brief Pain
Inventory (BPI) pain scores improved in 53–69% of patients with
pain scores greater than zero at baseline, with no significant
differences between treatment groups (Rosen et al, 2001, 2003).
In recent years, interest has increased in home care as an
alternative to hospital treatment. Several countries, including the
United Kingdom, Australia, and the United States, have developed
programmes to address this issue. In the United Kingdom, the
National Health Service launched a Cancer Plan designed to
improve patient access to care by providing home and community
treatment options (National Health Service, 2000). Australia
launched the Hospital in the Home pilot programme to provide
short-term home care as an alternative to hospitalisation (Depart-
ment of Human Services, 2003). Similarly, the US Medicare system
provides short-term Post-Acute Care benefits for homebound
individuals (Liu et al, 1999). Home care can provide several
advantages for patients and caregivers. In several studies, home
care was as effective as hospital care and resulted in fewer
hospitalisations, decreased pain, improved quality of life, in-
creased performance status, and greater patient satisfaction
(Vinciguerra et al, 1986; Ventafridda et al, 1989; Hughes et al,
1992; Shepperd et al, 1998; MacIntyre et al, 2002).
The 15-min infusion time required for zoledronic acid treatment
makes it ideal for home or community administration, particularly
for patients not receiving chemotherapy. Therefore, this study
investigated the efficacy and safety of zoledronic acid administered
in the community setting compared with the hospital setting
in breast cancer patients with X1 bone metastasis receiving
hormonal therapy.
PATIENTS AND METHODS
Patients
The study enrolled adult patients with a histologically confirmed
diagnosis of breast cancer and X1 bone metastasis confirmed by
conventional radiograph. Patients had to be receiving hormonal
therapy for their breast cancer and have an Eastern Cooperative
Oncology Group (ECOG) performance status p2. Patients were
not eligible if they were receiving chemotherapy or had abnormal
renal function, defined as a serum creatinine level 41.5 times the
upper limit of normal or a calculated creatinine clearance of
o60mlmin
 1.
Study design and treatment schedule
This was a phase IIIb, multicentre, randomised, open-label,
crossover study. The objective of the study was to determine
efficacy and safety of zoledronic acid administered in the
community setting vs the hospital setting. Patients received
zoledronic acid (4mg) via 15-min intravenous infusion every 3
weeks for up to 9 months. All patients received treatment in the
hospital setting for up to three cycles (hospital lead-in phase) to
ensure disease stabilisation on hormone therapy. Patients were
then randomised to receive treatment for three cycles in either the
community setting or the hospital setting. After the three cycles,
patients were crossed over to receive three cycles of treatment in
the opposite setting. Thus, patients received a total of nine
infusions over the course of the study (Figure 1). Infusion of
zoledronic acid in the community setting was carried out by nurses
from Healthcare at Home Limited (Burton-upon-Trent, UK). This
study adhered to Good Clinical Practice (Declaration of Helsinki,
Hospital lead-in phase
3 infusions 3 infusions 3 infusions
Hospital or community Hospital or community
Crossover
Completion
n = 84 n = 101
n = 56
n = 45
n = 127
Screening Randomisation Community/ 
hospital
Hospital/
community
Figure 1 Study design. Zoledronic acid (4mg) was administered intravenously via 15-min infusion every 3–4 weeks for a maximum of nine infusions. The
study was divided into a hospital lead-in phase with three infusions and two community vs hospital crossover phases with three infusions in each setting for a
total of nine infusions.
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sDirective 91/507/EEC) and was approved by Multi-Research Ethics
Committee. All patients signed informed consent.
Efficacy assessment
The primary end point was to compare the efficacy of zoledronic
acid administered in the community setting with the hospital
setting. This end point was measured by evaluating bone pain,
quality of life, performance status, resource utilisation, and patient
satisfaction. Pain was assessed using the BPI, which measures
intensity of pain and interference of pain with daily functioning
(Cleeland and Ryan, 1994). Patients rated their pain and the degree
to which pain limited their function at the time of response to the
questionnaire, as well as their worst, least, and average pain over
the previous 7 days. Quality of life was measured using the
European Organisation for Research and Treatment of Cancer
(Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) and
the corresponding disease-specific BR23 breast cancer module
(Aaronson et al, 1993; Sprangers et al, 1996). The EORTC QLQ-
C30 questionnaire incorporates nine multi-item scales: five
functional scales (physical, role (work and household activities),
cognitive, emotional, and social); three symptom scales (fatigue,
pain, and nausea and vomiting); and a global health and quality-
of-life scale (Aaronson et al, 1993). The BR23 breast cancer module
consists of 23 items covering symptoms and side effects related to
different treatment modalities, body image, sexuality, and future
perspective (Sprangers et al, 1996). The BPI was assessed at
baseline, at the end of each cycle, and at the final visit. The EORTC
QLQ-C30 and BR23 questionnaires were assessed at baseline, at the
end of each treatment phase (hospital lead-in, community
crossover, and hospital crossover), and at the final visit. Analyses
of BPI and EORTC QLQ-C30 data were compiled for the 10-visit
observation period: three cycles of the hospital lead-in phase, three
cycles of the community crossover phase, three cycles of the
hospital crossover phase, and final visit. Performance status was
assessed using the ECOG scale. Resource utilisation was assessed
by calculating time spent travelling to the hospital to receive the
three infusions after randomisation.
Safety assessment
The secondary end point was the safety and tolerability of
zoledronic acid and was assessed by monitoring serum creatinine,
calculated creatinine clearance, and the occurrence of adverse/
serious adverse events. Serum creatinine was measured in the
community setting using the i-STAT point-of-care analyser
(Abbott Diagnostics, Abbott Park, Il, USA). Decreased renal
function was defined as an increase in serum creatinine of X44
or X88mmoll
 1 from baseline for patients with baseline serum
creatinine of o124 or X124mmoll
 1, respectively, or at least twice
the baseline value. These criteria were standard across all Novartis
zoledronic acid registration protocols. Decreased renal function as
measured by calculated creatinine clearance was defined as X1
result more than 30% below baseline. Creatinine clearance was
calculated using the Cockcroft-Gault equation. A serious adverse
event was defined as any fatal or life-threatening event, any event
that required a prolonged hospitalisation, any event that was
significantly or permanently disabling or incapacitating, or any
event that required medical or surgical intervention to prevent
death, disability, or incapacitation.
Statistical analysis
The efficacy analysis was carried out on an intention-to-treat (ITT)
population defined as all patients who received X1 dose of trial
medication, provided baseline efficacy data, and from whom X1
postbaseline measurement was obtained. The end point measure-
ment for each randomised patient was the last postrandomisation
measurement carried forward to the end of the 3-month phase
(hospital or home care). Patients in the ITT population had to
provide efficacy data in all phases of the study.
Raw scores from the EORTC QLQ-C30 questionnaires were
transformed according to standard methods (Aaronson et al, 1993)
to produce derived scores (range, 0–100). The derived scores were
analysed using a mixed-effects model, in which period (second or
third set of three cycles) and treatment (community care or
hospital care) were fitted as fixed effects and subject fitted as a
random effect. Mean differences between treatments (community
care minus hospital care) were calculated and tested by analysis of
variance. Model assumptions were checked and found to be
adequately satisfied. Analyses were carried out using PROC
MIXED of SAS
s. For BPI, the composite pain score was derived
from the raw scores and analysed using a similar mixed model. All
hypothesis tests for the efficacy and safety analyses were two-
tailed, a¼0.05. Novartis UK Medical Information Processing and
Statistics carried out statistical analysis using SAS
s software,
version 8.2 (SAS Institute Inc.).
RESULTS
Patients
A total of 127 patients were screened, and 101 patients with X1
bone lesion secondary to breast cancer were enrolled (Figure 1).
After the hospital lead-in phase, patients were randomised to
treatment with 4mg zoledronic acid administered in the commu-
nity setting followed by the hospital setting (n¼56) or adminis-
tered in the hospital setting followed by the community setting
(n¼45). A total of 26 patients could not be randomised because of
early progression of disease during the three initial hospital
infusions. Of the 101 enrolled patients, 84 (83%) completed the
study (44 patients in the community/hospital group and 40
patients in the hospital/community group) and 79 (78%) patients
were available for analysis, constituting the ITT population. Patient
demographics and baseline disease characteristics were similar
between treatment groups (Table 1).
Safety
Zoledronic acid (4mg) was well tolerated. Renal function was
normal throughout the study for the majority of patients. Serum
Table 1 Patient demographic and baseline disease characteristics by
treatment group
Characteristic
Community/
hospital (n¼56)
Hospital/
community
(n¼45)
Mean (s.d.) age (years) 60 (11.8) 59 (10.7)
Range (years) 37–87 37–76
Race, n (%)
White 56 (100) 44 (98)
Black 0 1 (2)
ECOG status, n (%)
0 or 1 49 (88) 41 (91)
X2 6 (11) 4 (9)
Missing but scored 0 at visit 4 1 (1) 0
Mean (s.d.) BPI composite pain score 2.6 (1.7) 2.7 (2.4)
Baseline serum creatinine, n (%)
o124mmoll
 1 56 (100) 45 (100)
s.d.¼standard deviation; ECOG¼Eastern Cooperative Oncology Group; BPI¼Brief
Pain Inventory.
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screatinine levels increased in only four of the 127 (3%) evaluable
patients by 444mmoll
 1 above baseline. Mean serum creatinine
values were higher in the community phase of both treatment
groups compared with the hospital lead-in phase or the hospital
crossover phase; however, these fluctuations were related to the
use of an i-STAT handheld analyser (Abbott Diagnostics). The
differences between community and hospital serum creatinine
values were not significant and levels returned to near baseline
when patients returned to the hospital setting (Figure 2). All mean
serum creatinine values were within the generally recognised
normal range (54–98mmoll
 1). Creatinine clearance was
also normal for most patients; only 12 (9.4%) patients had one
or more results 430% below baseline, and the majority of these
patients only had one such decrease. Adverse events (regardless of
relationship to study drug) were mild – most commonly flu-like
symptoms, nausea, arthralgia, headache, pain, and vomiting
(Table 2). Severe adverse events were experienced by 32 of 127
(25%) evaluable patients; however, these events did not result in
any discontinuations from the study and only two events were
related to study medication. All serious adverse events were grade
3; no grade 4 serious adverse events were reported. Eight (6.3%)
patients died during the study: seven because of disease
progression and one because of acute cardiovascular events not
thought to be associated with zoledronic acid or their cancer.
Efficacy
BPI scores Over the 10-visit observation period, treatment with
zoledronic acid resulted in overall improvement in the composite
BPI score in the entire patient population compared with baseline
that did not achieve statistical significance (mean,  0.5; P¼0.077).
However, treatment with zoledronic acid resulted in significant
reductions in worst pain in the last 7 days (P¼0.008), average pain
in the last 7 days (P¼0.039), interference with general activity
(P¼0.012), interference with walking ability (Po0.001), inter-
ference with normal work (P¼0.005), interference with enjoyment
of life (P¼0.005), and interference with sleep (P¼0.015)
compared with baseline (Figure 3). All other assessments showed
small, nonsignificant changes from baseline.
Infusion of zoledronic acid in the community setting achieved
significantly greater improvement in BPI pain scores compared
with the hospital crossover setting (Figure 3). Significantly greater
improvements were reported in the BPI composite score
(P¼0.008), worst pain in the last 7 days (P¼0.021), average pain
in the last 7 days (P¼0.003), pain right now (P¼0.013),
interference with general activity (Po0.001), interference with
mood (P¼0.036), and interference with walking ability (Po0.001)
in the community crossover phase compared with the hospital
crossover phase. In each case, pain scores significantly improved
in the community phase compared with baseline, whereas no
significant changes were reported in the hospital crossover phase.
Interference with normal work improved significantly greater in
the community crossover phase compared with the hospital
crossover phase (Po0.001), and this score improved significantly
in both the community crossover phase (P¼0.011) and the
hospital crossover phase (P¼0.015) compared with baseline.
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Figure 2 Mean serum creatinine values remained stable throughout treatment with zoledronic acid. Serum creatinine values were measured at baseline
(BL), after each cycle, and at follow-up. Measurements during home administration were performed using an i-STAT handheld analyser (Abbott Diagnostics).
Table 2 Adverse events (all grades), regardless of relation to study drug,
occurring in X10% of patients (safety-evaluable population)
Patients, n (%)
Adverse event Zoledronic acid 4mg (n¼127)
Any event 121 (95)
Influenza-like illness 40 (31)
Nausea 30 (24)
Arthralgia 27 (21)
Headache 25 (20)
Pain NOS 25 (20)
Vomiting NOS 21 (17)
Back pain 19 (15)
Constipation 17 (13)
Fatigue 17 (13)
Pain in limb 13 (10)
NOS¼not otherwise specified.
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sEORTC QLQ-C30 score Over the 10-visit observation period,
treatment with zoledronic acid resulted in a significant 5% increase
in mean scores for overall global health status compared with
baseline (P¼0.013). Specifically, 36 of the 79 (46%) patients
available for analysis reported increases in global health status, 24
(30%) patients reported no change, and 19 (24%) patients reported
decreased health status. Assessment of the functional scales
showed significant increases in mean scores for physical
functioning (6% increase; P¼0.013), emotional functioning (8%
increase; P¼0.005), and social functioning (7% increase;
P¼0.043) compared with baseline (Figure 4). Overall cognitive
and role scales remained stable throughout the course of the study.
Infusion of zoledronic acid in the community crossover setting
resulted in significantly greater improvement in physical function-
ing (P¼0.018), role functioning (P¼0.001), and social functioning
(P¼0.026) compared with the hospital crossover setting (Figure 5).
Physical functioning scores during the community crossover phase
showed a significant mean increase of 3% from baseline
(P¼0.002) compared with a nonsignificant improvement in the
hospital crossover phase. Similarly, role functioning scores
increased significantly vs baseline in the community crossover
phase (mean increase¼8%; P¼0.007), whereas a nonsignificant
increase was reported during the hospital crossover phase. Social
functioning scores were stable compared with baseline in both
community crossover and hospital crossover phases.
Assessment of patient perception of symptoms revealed
significantly greater improvement in pain and diarrhoea scores
in the community crossover phase (P¼0.031) compared with
the hospital crossover phase (P¼0.01). Pain scores improved
significantly by a mean of 4% from baseline in the community
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Figure 3 Zoledronic acid significantly improved Brief Pain Inventory (BPI) pain scores. Brief Pain Inventory was assessed at baseline, at the end of each
cycle, and at final visit. Graph depicts mean change from baseline BPI scores reported during the hospital crossover phase, community crossover phase, and
overall (score reported at final visit after nine infusions). *Po0.05; wPo0.005 compared with baseline values.
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Figure 4 Zoledronic acid significantly improved EORTC QLQ-C30 quality-of-life scores. Graph depicts overall mean change from baseline quality-of-life
scores reported at final visit after nine infusions. *Po0.05 compared with baseline values. EORTC QLQ-C30¼European Organisation for Research and
Treatment of Cancer Quality of Life Core Questionnaire 30.
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scrossover phase (P¼0.022) compared with a nonsignificant
improvement in the hospital crossover phase. Similarly, diarrhoea
scores improved significantly by 5% from baseline in the
community phase (P¼0.005) compared with a nonsignificant
improvement during the hospital crossover phase. All other
symptoms remained stable, with changes o5%.
Patients also experienced significantly fewer financial difficulties
during the community crossover phase of the study compared with
the hospital crossover phase (P¼0.004). During the community
crossover phase, patients reported a significant mean decrease of
4% in financial difficulties (P¼0.029), whereas during the hospital
crossover phase a significant mean increase of 5% (P¼0.003) was
reported compared with baseline. For all EORTC QLQ-C30 scales,
an increase of 45% was considered to be clinically significant.
BR23 breast cancer module Over the course of the study, patients
reported significant declines in future perspective with a median
change of 0 and a mean decrease of 17% (Po0.0001) in the entire
patient population compared with baseline. However, sexual
function significantly increased (median change of 0 and mean
increase of 4%; P¼0.049). Body image and systemic therapy side
effects remained stable. Hair loss and sexual enjoyment had too
few respondents to assess meaningfully. Arm symptoms showed
significant differences between the community crossover and
hospital crossover settings. In the hospital crossover setting, arm
symptoms improved 3% (P¼0.004), whereas the community
setting arm symptoms worsened 4% (P¼0.076) compared with
baseline.
ECOG performance status No significant changes in performance
status were noted during the study compared with baseline
measurements. The majority of patients were either fully active or
restricted in physically strenuous activity.
Resource utilisation Time that patients spent travelling to the
hospital was calculated for the three hospital infusions of
zoledronic acid after randomisation. Patients spent a cumulative
time of more than 240h travelling to and from the hospital
(median, 2.5h for all three visits; range, 0.25–13.5h).
Patient satisfaction Overall, patients were satisfied with zole-
dronic acid treatment (Table 3). Patients were significantly more
satisfied when zoledronic acid was administered in the community
crossover setting compared with the hospital crossover setting.
Significant differences were noted in the percentage of patients
480% satisfied (94% for community vs 83% for hospital cross-
over; P¼0.048) and 100% satisfied (73% for community crossover
vs 51% for hospital crossover; P¼0.005).
DISCUSSION
Patients with breast cancer are at high risk for bone metastases,
resulting in significant skeletal complications and bone pain that
negatively affects their quality of life. Long-term treatment with
zoledronic acid (4mg) has been shown to reduce the risk of
skeletal complications in these patients by an additional 20%
compared with pamidronate, particularly in patients receiving
hormonal therapy, in whom the risk was reduced by an additional
30% (Rosen et al, 2003). Zoledronic acid is suited to home
administration because of its short infusion time and its favourable
safety profile. Furthermore, patients with breast cancer receiving
hormonal therapy are particularly suited to home care because of
the apparent earlier stage of their disease and better prognosis vs
patients receiving chemotherapy. Therefore, this randomised
crossover study investigated the efficacy and safety of zoledronic
acid in the community setting vs the hospital setting in breast
cancer patients with bone metastases receiving hormonal therapy.
Results showed that zoledronic acid was safe in both the
community and hospital settings, and analysis of BPI and EORTC
QLQ-C30 quality-of-life scores demonstrated that zoledronic acid
significantly improved composite pain scores and overall quality of
life compared with baseline, particularly when administered in the
community setting.
In this study, zoledronic acid was safe and well tolerated;
adverse events were mild, and no patient experienced a sustained
decrease in renal function in either the community or hospital
setting. Fluctuations in home serum creatinine measurements were
noted but were related to the use of an i-STAT handheld analyser.
Importantly, mean serum creatinine values were always within the
normal range and returned to baseline during infusions in the
hospital, where values were measured in the hospital laboratory.
Analysis of BPI scores showed no changes in the overall
composite score at end of study compared with baseline; however,
significant decreases were noted in several subcategories. Notably,
a significant improvement was observed in many aspects of pain,
although these scores were relatively low at baseline. A recent
analysis of treatment with zoledronic acid in women with
metastatic breast cancer demonstrated that better baseline scores
were associated with less improvement after treatment, whereas
poorer initial scores were associated with higher rates of change
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Figure 5 Zoledronic acid achieved significantly greater improvement
in EORTC QLQ-C30 quality-of-life scores when administered in the
community crossover phase compared with the hospital crossover phase.
The EORTC QLQ-C30 questionnaire was assessed at baseline, at the end
of each treatment phase (hospital lead-in, community crossover, and
hospital crossover), and at final visit. Graph depicts mean change from
baseline quality-of-life scores reported during the hospital crossover phase
and the community crossover phase. *Po0.05; wPo0.001 compared with
hospital lead-in score. EORTC QLQ-C30¼European Organisation for
Research and Treatment of Cancer Quality of Life Core Questionnaire 30.
Table 3 Patient satisfaction with zoledronic acid treatment in hospital vs
community setting
Patients, n (%)
Satisfaction 480% Satisfaction¼100%
Hospital lead-in 57 (79) 32 (44)
Community 74 (94) 58 (73)
Hospital crossover 65 (83) 40 (51)
Final visit 72 (91) 51 (65)
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s(Weinfurt et al, 2004). Therefore, although the improvements in
pain scores reported by patients in this trial were small, the
differences were significant, demonstrating that the overall well-
being of these patients improved. Comparison of community vs
hospital infusion of zoledronic acid showed that composite pain
scores significantly improved in the community setting. This result
confirms a previous study demonstrating that home care of
patients with advanced cancer decreased narcotic and analgesic
requirements compared with hospital care (Vinciguerra et al,
1986), and potentially reflects the increased satisfaction often
experienced by patients receiving home care (Ventafridda et al,
1989; Hughes et al, 1992).
Previously, the EORTC QLQ-C30 quality-of-life questionnaire
has not been used for the assessment of zoledronic acid efficacy.
This questionnaire provides a comprehensive assessment of the
quality of life of cancer patients participating in clinical trials.
According to this questionnaire, global health status improved
significantly over the course of the study, as did physical, social,
and emotional functioning (Figure 4). In all cases, these
improvements were 45% and considered clinically significant.
Furthermore, these improvements were observed despite the fact
that quality-of-life scores were only assessed every 3 months,
resulting in some variability. These results are consistent with the
pivotal phase III study of zoledronic acid vs pamidronate in
patients with multiple myeloma or breast cancer and bone
metastases, wherein significant increases in mean ECOG perfor-
mance status scores compared with baseline were achieved for
both treatment groups between months 15 and 25 (Rosen et al,
2003). Notably, physical and role functioning achieved signifi-
cantly greater improvement with zoledronic acid infusion in the
community setting compared with the hospital setting, most likely
because community treatment allowed patients to continue with
their normal work routine. In a recent randomised, crossover trial
of home-based vs hospital-based chemotherapy in Australia, home
therapy was significantly preferred over hospital therapy
(Po0.0001) (Rischin et al, 2000). Reasons cited for this preference
included the elimination of travel, reduced treatment anxiety,
reduced caregiver burden, and the ability to continue other duties.
The benefit of home care on quality of life has also been
documented in other National Health Service programmes
developed in the United Kingdom, such as the home dialysis
programme for patients with end-stage renal failure instituted by
the National Institute for Clinical Excellence (2002).
In addition to improved patient satisfaction and quality of life,
home treatment may also reduce patient and healthcare costs.
Many studies reported decreased healthcare costs (reductions
ranging from 18 to 85%) for treatment provided in the home
compared with the hospital (Hughes et al, 1992; Ventafridda et al,
1989). A randomised trial conducted by the US Department of
Veterans Affairs evaluating the cost effectiveness of home care
compared with customary hospital care for 171 terminally ill
patients reported that patients receiving home care used 5.9 fewer
hospital days (P¼0.03), resulting in a significant 47% per capita
savings in hospital costs (P¼0.02) and an 18% reduction in total
per capita healthcare costs (Hughes et al, 1992). This study also
demonstrated a significant increase in patient (P¼0.02) and
caregiver (P¼0.005) satisfaction with home care after 1 month of
treatment. Therefore, home care may not only result in lowered
healthcare costs and reduced expenses, but also a more satisfying
and comfortable lifestyle for patients and caregivers.
In summary, zoledronic acid is a safe and effective treatment for
skeletal complications resulting from bone metastases in patients
with breast cancer. Furthermore, infusion of zoledronic acid in the
community setting significantly improved pain and quality of life
compared with hospital administration, and patients were more
satisfied with treatment in the home. A cost analysis that includes
cost of treatment and patient out-of-pocket expenses needs to be
conducted to assess fully potential economic benefits for patients
and the healthcare system. However, the short infusion time of
zoledronic acid and the patient benefits demonstrated by this
study suggest that zoledronic acid is an excellent candidate for
administration in the community setting.
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